Last reviewed · How we verify
Tobramycin and dexamethasone ophthalmic suspension
Tobramycin kills bacteria by inhibiting protein synthesis, while dexamethasone reduces inflammation and immune response in the eye.
Tobramycin kills bacteria by inhibiting protein synthesis, while dexamethasone reduces inflammation and immune response in the eye. Used for Bacterial conjunctivitis, Bacterial keratitis, Ocular inflammation associated with bacterial infection.
At a glance
| Generic name | Tobramycin and dexamethasone ophthalmic suspension |
|---|---|
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | Antibiotic/corticosteroid combination |
| Target | Bacterial ribosome (tobramycin); glucocorticoid receptor (dexamethasone) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Tobramycin is an aminoglycoside antibiotic that binds to bacterial ribosomes and prevents protein synthesis, effectively killing susceptible gram-negative and gram-positive bacteria. Dexamethasone is a potent corticosteroid that suppresses inflammatory mediators and immune cell activity, reducing swelling, redness, and discomfort. Together, they provide both antimicrobial and anti-inflammatory effects for ocular infections and inflammation.
Approved indications
- Bacterial conjunctivitis
- Bacterial keratitis
- Ocular inflammation associated with bacterial infection
Common side effects
- Ocular irritation or discomfort
- Conjunctival erythema
- Lid edema
- Transient blurred vision
Key clinical trials
- Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery (PHASE4)
- Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents (PHASE4)
- Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery (PHASE3)
- To Study Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension (EARLY_PHASE1)
- A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis (PHASE3)
- A Bioequivalence Study of Tobradex AF (PHASE3)
- Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis (PHASE3)
- Zylet vs TobraDex in Blepharokeratoconjunctivitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: